The new facility, located near the company’s existing Suzhou site, will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare’s brands in China and the Asia-Pacific region. It will support production of additional products in the future.
Pfizer Consumer Healthcare Asia Pacific and Europe, Middle East and Africa regional president Andy Schmeltz said: "Asia Pacific is a large and rapidly growing region for Pfizer Consumer Healthcare and our new plant in Suzhou will give us the production capacity we need to meet increasing demand for our brands, particularly in China."
In order to help support innovation in the region, the company also plans to eventually house a research and development facility on the site.
The new $95m site design is expected to achieve Leadership in Energy and Environmental Design (LEED) certifications and will also include the most advanced technologies to reduce energy and water consumption.
To reduce energy consumption, the new facility will be fitted with high-efficiency manufacturing equipment, LED and solar powered lighting with automatic controls.
The facility will employ technologies to recycle waste heating and cooling and will make extensive use of natural lighting and shading.
The company’s existing Suzhou facility produces Centrum multivitamins, Caltrate dietary supplements, Robitussin cough and cold products, antibiotics as well as other prescription and over-the-counter (OTC) products.